GLP-1 Peptides and Muscle Loss: What the Research Actually Shows

One of the most common concerns among people starting semaglutide or tirzepatide is muscle loss. It is a fair question. GLP-1 peptides can drive substantial weight reduction — and any significant weight loss carries the possibility of losing lean tissue alongside fat. But the clinical data tells a more nuanced story than most social media discourse suggests.

Here is what the major trials actually found.

What the DXA Data Shows

The most reliable way to assess body composition changes during a clinical trial is dual-energy X-ray absorptiometry (DXA), which separates fat mass from lean soft tissue. Two major phase 3 trials have published DXA substudies.

SURMOUNT-1 (tirzepatide, 72 weeks): The DXA substudy enrolled 160 participants from the main trial. At the highest dose, participants lost an average of 22.1 kg total. Of that, roughly 75% was fat mass and 25% was lean mass — meaning approximately 5.7 kg of lean tissue was lost alongside 16.4 kg of fat. The ratio of lean-to-fat mass loss was consistent across all subgroups analyzed, including by age and sex.

STEP-1 (semaglutide 2.4 mg, 68 weeks): The semaglutide data shows a somewhat different split. In that DXA substudy, lean mass represented approximately 39–45% of total weight lost. On average, lean mass declined by around 6.9 kg against a total loss of roughly 15.3 kg. The relative lean mass proportion of total body weight increased modestly — indicating that while absolute lean mass fell, the fraction of the body that was lean actually improved.

Both drugs cause lean mass loss in absolute terms. But the large majority of weight lost in both trials was fat mass, and relative lean mass fraction improved.

Is This Different From Other Weight Loss Methods?

Here is the piece of context that often gets left out: lean mass loss during weight reduction is not unique to GLP-1 peptides. A 2025 meta-analysis examining multiple weight-loss interventions found that lean mass accounted for approximately 25–39% of weight lost with semaglutide or tirzepatide — broadly comparable to what happens with caloric restriction through diet alone. By comparison, intensive lifestyle interventions that included resistance training reduced the lean mass fraction of weight loss to roughly 17.5%.

This framing matters. The question is not whether GLP-1s cause muscle loss — some lean tissue loss accompanies any significant caloric deficit. The more useful question is whether the lean mass loss seen with GLP-1 therapy represents something metabolically or functionally harmful, and whether it can be mitigated.

What Happens to Muscle Function?

The SEMALEAN study (2025) offered an important data point on this. In adults with obesity on semaglutide 2.4 mg for 12 months, lean mass declined approximately 3 kg at seven months and then stabilized. But handgrip strength — a validated marker of functional muscle status — improved by 4.5 kg over the same period. Prevalence of sarcopenic obesity fell from 49% to 33% among participants.

The SURPASS-3 MRI substudy on tirzepatide added another layer: muscle volume changed proportionally to weight loss, but muscle fat infiltration — the deposition of fat within muscle tissue — decreased significantly beyond what weight loss alone would predict. High intramuscular fat is associated with insulin resistance and reduced functional capacity, so this reduction is metabolically favorable.

Losing lean mass on a DXA scan does not necessarily mean losing muscle function or muscle quality. Some of what DXA measures as lean soft tissue includes glycogen, water, and connective tissue — all of which shift with dietary changes and body remodeling. Functional strength data often tells a more complete story than raw lean mass numbers.

Who Is at Higher Risk?

Not everyone faces equal lean mass risk. Older adults, those starting with low baseline muscle mass, and individuals pursuing very large weight targets face greater risk of clinically meaningful lean tissue reduction. A 2024 review by Neeland and colleagues highlighted that muscle changes in younger, healthier adults are often adaptive and proportional — while in older populations or those with pre-existing sarcopenia, active intervention is warranted.

If you are over 60, starting from a low muscle baseline, or have a history of prior significant weight loss, lean mass protection deserves more active planning than it does for a younger adult with adequate baseline muscle.

What the Evidence Says About Prevention

The most structured intervention data comes from the LEAN-PREP trial, an ongoing randomized controlled study examining whether resistance training (three sessions per week, progressing in volume) combined with higher protein intake (targeting approximately 1.6 grams per kilogram of body weight daily) preserves muscle mass and function in adults starting semaglutide or tirzepatide. The primary outcome is MRI-measured quadriceps cross-sectional area. Results are expected in the coming years, but the mechanistic rationale is well-grounded in the existing exercise science literature.

What is already clear from non-drug weight-loss research is that resistance training reliably attenuates lean mass loss during caloric deficits. The open question LEAN-PREP addresses is whether that protection fully translates when the caloric deficit is GLP-1-mediated, and at what protein threshold the benefit is most consistent.

Current thinking among practitioners working with GLP-1 patients converges on a few principles. Resistance training two to three times per week, with an emphasis on compound movements, appears to matter more than training volume. Protein intake recommendations in the literature cluster around 1.2–1.6 grams per kilogram of body weight, though individual needs vary. Gradual dose titration — where clinically appropriate — may reduce the rate of weight loss to a pace the body can better adapt to. For older adults or those with baseline sarcopenia concerns, periodic DEXA monitoring provides a more objective check than body weight alone.

These are not prescriptive recommendations. Individual circumstances vary considerably, and anyone on GLP-1 therapy should work with their prescribing clinician on a protocol suited to their situation.

The Bottom Line

GLP-1 peptides like semaglutide and tirzepatide do cause some lean mass loss as part of total weight reduction. The major DXA substudies put this at roughly 25–45% of total weight lost, consistent with what happens during dietary weight loss more broadly. Muscle function markers often hold steady or improve despite absolute lean mass declines, and intramuscular fat infiltration decreases with tirzepatide — a favorable metabolic shift. Higher-risk populations, particularly older adults, benefit from more active lean mass protection strategies.

For most people, the combination of resistance training and adequate protein remains the most evidence-supported approach to preserving lean mass during GLP-1 therapy.

For those exploring GLP-1 options, the PepEvolution Provider Directory includes telehealth clinicians experienced in prescribing semaglutide and tirzepatide. The Price Index covers compounded availability across vendors. For a side-by-side comparison of the two compounds by clinical trial data, see Tirzepatide vs. Semaglutide: What the Clinical Trials Actually Show.